Dupilumab clinical trials
Also written Dupixent, REGN668 and SAR231893.
ClinicalTrials.gov finds 312 studies for dupilumab. How that becomes 180 here
Every study that search finds has been read, to see whether and how it gives dupilumab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 312Found by its intervention search · See all 312 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 258 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −10
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic DermatitisNCT04975438 · Earlier treatment, not given in this studyReport a problem
- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With DupilumabNCT05369403 · Earlier treatment, not given in this studyReport a problem
- An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing DupilumabNCT05394792 · Earlier treatment, not given in this studyReport a problem
- Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With DupilumabNCT05602207 · Earlier treatment, not given in this studyReport a problem
- Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With DupilumabNCT05694884 · Earlier treatment, not given in this studyReport a problem
- Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint InhibitorsNCT05834413 · The search matches the record elsewhere; not givenReport a problem
- A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of LutikizumabNCT06524635 · Earlier treatment, not given in this studyReport a problem
- Tralokinumab for Dupilumab FailuresNCT06773455 · Earlier treatment, not given in this studyReport a problem
- Expression of TSLP Isoforms in AsthmaNCT07786870 · The search matches the record elsewhere; not givenReport a problem
- A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other TherapiesNCT07887867 · Earlier treatment, not given in this studyReport a problem
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 303Give dupilumab to participants
- −90Observe patients on it, or give it outside a trial
- −1Use it as a tool: an imaging tracer or a test of drug response
- −26Compare another treatment with it
- −6Give it beside what is tested
- 180Test it: the count on this site
Get an email when these change. Save the dupilumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Mar 2017 · DUPIXENT · BLA 761055 (FDA, Drugs@FDA)
- European Union
- 26 Sept 2017 · Dupixent · EMEA/H/C/004390 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
180 studies that test it; most in 2020 (25)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 15 |
| 2019 | 10 |
| 2020 | 25 |
| 2021 | 21 |
| 2022 | 13 |
| 2023 | 21 |
| 2024 | 19 |
| 2025 | 10 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 93 · Other 87
Sanofi (52) · Regeneron Pharmaceuticals (40) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Icahn School of Medicine at Mount Sinai (5) · Brigham and Women's Hospital (3) · Rigshospitalet, Denmark (3) · University of Michigan (3) · Mayo Clinic (3)
Often tested with
Tested in the same studies.
Omalizumab (3) · Cemiplimab (3) · Itepekimab (2) · Mepolizumab (1) · Triamcinolone Acetonide (1) · Triamcinolone (1) · Hydrocortisone (1) · Grazax (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 8 phase 3 studies under way
Dupilumab is the comparator. A study of two new drugs counts under both.
- 2Upadacitinib · AbbVie · next primary completion Nov 2026
- 1Remibrutinib · Novartis Pharmaceuticals · next primary completion Feb 2027
- 1Tilrekimig · Pfizer · next primary completion Sep 2028
- 1GS 101 · Jiangsu Genscend Biopharmaceutical Co., Ltd · next primary completion Apr 2027
New treatments tested with it · 1 most studied
New when their studies opened, with dupilumab beside them; studies of each.
Reaching primary completion within a year · 19, 3 in phase 3
Studies that test dupilumab, phase 3 first.
- Jan 2027Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationPhase 2/3 · Wei-Che Ko
- Jun 2027Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)Phase 3 · Sanofi
- Oct 2027A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisPhase 3 · Sanofi
- Nov 2026Dupilumab Effects Against Aeroallergen ChallengePhase 2 · The University of Texas Health Science Center at San Antonio
- Nov 2026DUPIlumab Dose REDUCtion in Patients With Controlled Atopic EczemaPhase 4 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Dec 2026Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCPhase 1/2 · Icahn School of Medicine at Mount Sinai
- Dec 2026Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsPhase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Dec 2026Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and AdolescentsPhase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Jan 2027Investigating Dupilumab's Effect in Asthma by GenotypePhase 4 · Boston Children's Hospital
- Feb 2027A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisPhase 4 · Sanofi
Studies
Open first, then newest update. How each study uses dupilumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 180
- Ethnic Differences in Mechanisms of Action of DupilumabRecruitingPhase 4University of MichiganNCT05268107Ethnic differences in how it worksWritten as DupilumabReport a problem
- Biologics in Chronic Rhinosinusitis With Nasal PolyposisRecruitingPhase 4Medical University of South CarolinaNCT06824649One of three biologics compared in nasal polypsReport a problem
- Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06477653Added to anti-eosinophil biologics in hypereosinophilic syndromeWritten as dupilumabReport a problem
- A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in AsthmaRecruitingPhase 3Université de SherbrookeNCT07309614For clinical remission in asthmaReport a problem
- Dupilumab in Major Depressive DisorderRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07908563In major depressive disorderWritten as Dupilumab InjectionReport a problem
- A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisNot yet recruitingPhase 4SanofiNCT07905547In Indian adults with atopic dermatitisWritten as DupilumabReport a problem
- Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory ClinicRecruitingPhase 2Akron Children's HospitalNCT06226610In refractory post-burn itchWritten as DupilumabReport a problem
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.RecruitingPhase 4SanofiNCT07053423On airway inflammation in COPDWritten as DupilumabReport a problem
- This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring HospitalizationRecruitingPhase 4Regeneron PharmaceuticalsNCT07587658After a severe COPD exacerbation, with usual careWritten as dupilumabReport a problem
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)RecruitingPhase 3SanofiNCT05263206In chronic pruritus of unknown originWritten as DupilumabReport a problem
- A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisRecruitingPhase 3SanofiNCT06293053In children with prurigo nodularisWritten as DupilumabReport a problem
- Withdrawal of Dupilumab in Severe AsthmaRecruitingPhase 4University Hospital, ToulouseNCT06818019Stopping it in severe asthmaReport a problem
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisRecruitingPhase 3Regeneron PharmaceuticalsNCT07112378In small children with eosinophilic esophagitisWritten as dupilumabReport a problem
- Dupilumab in the Treatment of Pediatric Alopecia AreataRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT05866562In children with alopecia areataWritten as DupilumabReport a problem
- Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung CancerRecruitingNot applicableCentre hospitalier de l'Université de Montréal (CHUM)NCT06743581With cemiplimab before surgery in early lung cancerWritten as DupilumabReport a problem
- Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)Enrolling by invitationPhase 3SanofiNCT06191315In children aged 2 to 5 with asthma (TREKIDS)Written as DupilumabReport a problem
- Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver MetastasesRecruitingPhase 1/2Dan FengNCT07277322With toripalimab before surgery for colorectal liver metastasesWritten as DupilumabReport a problem
- Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe AsthmaRecruitingPhase 4Sally E. Wenzel MDNCT04743791On mucociliary clearance in asthmaWritten as DupilumabReport a problem
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCRecruitingPhase 1/2Icahn School of Medicine at Mount SinaiNCT06088771With cemiplimab before surgery in early lung cancerWritten as DupilumabReport a problem
- Regeneron AA Multicenter (Dupilumab)RecruitingPhase 2Emma GuttmanNCT05551793In alopecia areataWritten as DupilumabReport a problem
See all 180 studies that test dupilumab →
Behind its US label · 23 — the studies the FDA label of DUPIXENT describes
From the Clinical Studies section of DUPIXENT (2026-04), as openFDA has it. A study the site does not hold is left out.
- An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled AsthmaCompletedPhase 2SanofiNCT01854047Report a problem
- Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Regeneron PharmaceuticalsNCT02260986Report a problem
- Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Regeneron PharmaceuticalsNCT02277743Report a problem
- Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Regeneron PharmaceuticalsNCT02277769Report a problem
- A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)CompletedPhase 3Regeneron PharmaceuticalsNCT02395133Report a problem
- Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)CompletedPhase 3SanofiNCT02414854Report a problem
- Evaluation of Dupilumab in Patients With Severe Steroid Dependent AsthmaCompletedPhase 3SanofiNCT02528214Report a problem
- Controlled Clinical Study of Dupilumab in Patients With Nasal PolypsCompletedPhase 3SanofiNCT02898454Report a problem
- A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal PolypsCompletedPhase 3SanofiNCT02912468Report a problem
- Evaluation of Dupilumab in Children With Uncontrolled AsthmaCompletedPhase 3SanofiNCT02948959Report a problem
- Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic DermatitisCompletedPhase 3Regeneron PharmaceuticalsNCT03054428Report a problem
- Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)CompletedPhase 3Regeneron PharmaceuticalsNCT03345914Report a problem
- Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)CompletedPhase 2/3Regeneron PharmaceuticalsNCT03346434Report a problem
- Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)CompletedPhase 3Regeneron PharmaceuticalsNCT03633617Report a problem
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationCompletedPhase 3SanofiNCT03930732Report a problem
- Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)CompletedPhase 3SanofiNCT04180488Report a problem
- Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)CompletedPhase 3SanofiNCT04183335Report a problem
- Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)CompletedPhase 3SanofiNCT04202679Report a problem
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous PemphigoidCompletedPhase 2/3Regeneron PharmaceuticalsNCT04206553Report a problem
- Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)CompletedPhase 3Regeneron PharmaceuticalsNCT04394351Report a problem
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)CompletedPhase 3Regeneron PharmaceuticalsNCT04417894Report a problem
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationCompletedPhase 3SanofiNCT04456673Report a problem
- Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)CompletedPhase 3SanofiNCT04684524Report a problem
Tested on its own · 118 — no other medicine in its arm
- Ethnic Differences in Mechanisms of Action of DupilumabRecruitingPhase 4University of MichiganNCT05268107Ethnic differences in how it worksWritten as DupilumabReport a problem
- Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06477653Added to anti-eosinophil biologics in hypereosinophilic syndromeWritten as dupilumabReport a problem
- Dupilumab in Major Depressive DisorderRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07908563In major depressive disorderWritten as Dupilumab InjectionReport a problem
- A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisNot yet recruitingPhase 4SanofiNCT07905547In Indian adults with atopic dermatitisWritten as DupilumabReport a problem
- Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory ClinicRecruitingPhase 2Akron Children's HospitalNCT06226610In refractory post-burn itchWritten as DupilumabReport a problem
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.RecruitingPhase 4SanofiNCT07053423On airway inflammation in COPDWritten as DupilumabReport a problem
- This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring HospitalizationRecruitingPhase 4Regeneron PharmaceuticalsNCT07587658After a severe COPD exacerbation, with usual careWritten as dupilumabReport a problem
- A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisRecruitingPhase 3SanofiNCT06293053In children with prurigo nodularisWritten as DupilumabReport a problem
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisRecruitingPhase 3Regeneron PharmaceuticalsNCT07112378In small children with eosinophilic esophagitisWritten as dupilumabReport a problem
- Dupilumab in the Treatment of Pediatric Alopecia AreataRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT05866562In children with alopecia areataWritten as DupilumabReport a problem
- Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)Enrolling by invitationPhase 3SanofiNCT06191315In children aged 2 to 5 with asthma (TREKIDS)Written as DupilumabReport a problem
- Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe AsthmaRecruitingPhase 4Sally E. Wenzel MDNCT04743791On mucociliary clearance in asthmaWritten as DupilumabReport a problem
- Regeneron AA Multicenter (Dupilumab)RecruitingPhase 2Emma GuttmanNCT05551793In alopecia areataWritten as DupilumabReport a problem
- Molecular Signatures of Cutaneous Dupilumab ResponseRecruitingPhase 4University of California, San FranciscoNCT05858619Molecular signatures of response in the skinWritten as DupilumabReport a problem
- Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin DisordersRecruitingEarly Phase 1Northwestern UniversityNCT05649098In itchy genetic inflammatory skin disordersWritten as DupilumabReport a problem
- Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic DermatitisRecruitingPhase 4Northwestern UniversityNCT05042258On sleep and itch in children with atopic dermatitisWritten as DupilumabReport a problem
- Complete Remission After Treatment With Biologics for Nasal PolypsRecruitingPhase 4Rigshospitalet, DenmarkNCT07268313Stopping it after complete remission in nasal polypsWritten as DUPIXENT®Report a problem
- Viral Infection in Asthma (VIA) StudyRecruitingPhase 4University of VirginiaNCT04380038On viral infection in asthmaWritten as Dupilumab Injectable ProductReport a problem
- Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNPRecruitingPhase 4University of VirginiaNCT05094570On staphylococcal colonisation in nasal polypsWritten as Dupilumab Prefilled SyringeReport a problem
- Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With PolypsNot yet recruitingPhase 4Dr. Andrew Thamboo, MDNCT06556264Immune effects in asthma with nasal polypsWritten as DupilumabReport a problem
Showing 20 of 118. See all 118 →
Tested with established drugs · 35 — they are given beside it
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)RecruitingPhase 3SanofiNCT05263206In chronic pruritus of unknown originWritten as DupilumabReport a problem
- Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerRecruitingEarly Phase 1Rima PatelNCT06637306With pembrolizumab and chemotherapy before surgery in triple-negative breast cancerWritten as DupilumabReport a problem
- Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)RecruitingPhase 4University of California, San DiegoNCT06665971On oesophageal muscle function in eosinophilic esophagitisWritten as Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]Report a problem
- Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsCompletedPhase 1SanofiNCT07646548Coformulated with berahyaluronidase alfa against it aloneWritten as Dupilumab coformulated with berahyaluronidase alfaReport a problem
- Olfactory Outcomes of Dupilumab Treatment for Nasal PolyposisCompletedPhase 4London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT04869436On smell in nasal polyposisWritten as Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]Report a problem
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous PemphigoidCompletedPhase 2/3Regeneron PharmaceuticalsNCT04206553On the US labelIn bullous pemphigoidWritten as dupilumabReport a problem
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingPhase 2/3Wei-Che KoNCT05535738One of six biologics given before a contact allergen challengeWritten as DupilumabReport a problem
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled AsthmaActive, not recruitingPhase 4Regeneron PharmaceuticalsNCT06572228Added to medium-dose ICS/LABA, against escalating the steroidWritten as dupilumabReport a problem
- Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)CompletedPhase 3SanofiNCT03560466Long-term in children with asthma (EXCURSION)Written as Dupilumab (SAR231893/REGN668)Report a problem
- Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic EsophagitisCompletedPhase 4Children's Hospital of PhiladelphiaNCT05247866To ease food reintroduction in eosinophilic esophagitisWritten as DupilumabReport a problem
- Dupilumab in Chinese Adult Participants With CRSwNPCompletedPhase 3SanofiNCT05878093In Chinese adults with nasal polypsWritten as DupilumabReport a problem
- Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular EczemaActive, not recruitingPhase 2Technical University of MunichNCT04600362In nummular eczemaWritten as Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]Report a problem
- Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)CompletedPhase 3SanofiNCT04183335On the US labelIn prurigo nodularis (PRIME)Written as Dupilumab SAR231893Report a problem
- Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)CompletedPhase 3SanofiNCT04202679On the US labelIn prurigo nodularis (PRIME2)Written as Dupilumab SAR231893Report a problem
- Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)CompletedPhase 3SanofiNCT04681729In cold urticaria (LIBERTY-CINDU CUrIADS)Written as Dupilumab SAR231893Report a problem
- Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)CompletedPhase 3SanofiNCT04180488On the US labelIn chronic spontaneous urticaria (LIBERTY-CSU CUPID)Written as Dupilumab SAR231893Report a problem
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationCompletedPhase 3SanofiNCT04456673On the US labelIn COPD with type 2 inflammation (NOTUS)Written as Dupilumab SAR231893Report a problem
- Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)TerminatedPhase 3Emory UniversityNCT05545072Added after surgery in allergic fungal rhinosinusitisWritten as DupilumabReport a problem
- Dupilumab for Prevention of Recurrence of CRSwNP After ESSCompletedPhase 4Centre hospitalier de l'Université de Montréal (CHUM)NCT04596189To prevent nasal polyp recurrence after sinus surgeryWritten as Dupilumab 300 MG in 2 ML Prefilled SyringeReport a problem
- Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal PolyposisActive, not recruitingPhase 2University of South FloridaNCT04430179In eosinophilic chronic sinusitis without polypsWritten as Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]Report a problem
Showing 20 of 35. See all 35 →
Tested in a combination · 27 — another drug in the study is under test too
- Biologics in Chronic Rhinosinusitis With Nasal PolyposisRecruitingPhase 4Medical University of South CarolinaNCT06824649One of three biologics compared in nasal polypsReport a problem
- A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in AsthmaRecruitingPhase 3Université de SherbrookeNCT07309614For clinical remission in asthmaReport a problem
- Withdrawal of Dupilumab in Severe AsthmaRecruitingPhase 4University Hospital, ToulouseNCT06818019Stopping it in severe asthmaReport a problem
- Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung CancerRecruitingNot applicableCentre hospitalier de l'Université de Montréal (CHUM)NCT06743581With cemiplimab before surgery in early lung cancerWritten as DupilumabReport a problem
- Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver MetastasesRecruitingPhase 1/2Dan FengNCT07277322With toripalimab before surgery for colorectal liver metastasesWritten as DupilumabReport a problem
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCRecruitingPhase 1/2Icahn School of Medicine at Mount SinaiNCT06088771With cemiplimab before surgery in early lung cancerWritten as DupilumabReport a problem
- Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.Enrolling by invitationEarly Phase 1Mayo ClinicNCT07358234Against oral budesonide on oesophageal diameterWritten as Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]Report a problem
- Dupilumab Therapy in Nephrotic Syndrome in ChildrenRecruitingPhase 2National University Hospital, SingaporeNCT07091175In childhood nephrotic syndromeWritten as DupilumabReport a problem
- Tapering of Biologics in Chronic Rhinosinusitis With Nasal PolypsRecruitingPhase 4Rigshospitalet, DenmarkNCT07187583Longer dosing intervals of biologics, it among themReport a problem
- Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoERecruitingPhase 2University of Colorado, DenverNCT06705387Against topical fluticasone in stenotic eosinophilic esophagitisWritten as DupilumabReport a problem
- Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and EndotypingRecruitingPhase 4University of California, San DiegoNCT06385236Against benralizumab, for pharmacogenomic prediction in asthmaWritten as DupilumabReport a problem
- PD-1 +/- IL-4 Inhibition in ER+ Breast CancerNot yet recruitingPhase 2Ottawa Hospital Research InstituteNCT05967884With cemiplimab in ER-positive breast cancerWritten as Arm A: Cemiplimab, Arm B: Cemiplimab + DupilumabReport a problem
- Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic DermatitisCompletedPhase 4Nantes University HospitalNCT05642208Step-down dosing to keep remissionReport a problem
- A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton SyndromeTerminatedPhase 2/3University Hospital, ToulouseNCT04244006Against placebo in Netherton syndromeReport a problem
- Dupilumab_Metastatic NSCLCActive, not recruitingPhase 1/2Thomas MarronNCT05013450With PD-1 or PD-L1 blockade in lung cancerWritten as DupilumabReport a problem
- Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin AnalysisCompletedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT05436535Skin transcriptomics on treatmentWritten as DupilumabReport a problem
- Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)CompletedPhase 2Stanford UniversityNCT03679676Alone and with omalizumab beside multi-food oral immunotherapyWritten as DupilumabReport a problem
- Grass Pollen Immunotherapy Plus Dupilumab for Tolerance InductionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04502966With grass pollen immunotherapy for toleranceWritten as Dupixent®Report a problem
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsCompletedPhase 4SanofiNCT04998604Against omalizumab in type 2 asthma (EVEREST)Written as DupilumabReport a problem
- A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingPhase 4Rigshospitalet, DenmarkNCT05942222Head to head against mepolizumab in nasal polypsWritten as dupilumabReport a problem
Showing 20 of 27. See all 27 →
Beside an established treatment under test · 3 — an approved drug, surgery or radiation is what the study tests
Tested with dupilumab: apremilast 1 · tofacitinib 1
- Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD PatientsNot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06465732In every armTofacitinib added to it, against it aloneWritten as DupilumabReport a problem
- Dupixent and Narrowband UVB for Atopic DermatitisRecruitingPhase 4Psoriasis Treatment Center of Central New JerseyNCT05285839In every armNarrowband UVB added to itWritten as DupixentReport a problem
- Apremilast 30 mg Twice Daily (BID) Combined With DupilumabCompletedPhase 2Tufts Medical CenterNCT04306965Apremilast added for patients it does not control enoughReport a problem
Beside a new treatment under test · 1 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with dupilumab: linvoseltamab 1
- Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food AllergyActive, not recruitingPhase 1Regeneron PharmaceuticalsNCT06369467In every armLinvoseltamab tested on top of it in severe food allergyWritten as dupilumabReport a problem
Beside supportive care · 2 — a supportive treatment or test is studied
- Virtual Reality for Pain Management During Dupilumab InjectionRecruitingNot applicableSt. Justine's HospitalNCT06182436Virtual reality against pain during its injectionReport a problem
- Gastrointestinal STRING Test With Oral ImmunotherapyTerminatedEarly Phase 1Stanford UniversityNCT04943744Beside a gut string test during oral immunotherapyReport a problem
As the comparator · 26 — what is tested is compared with dupilumab
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingPhase 3PfizerNCT07783425Comparator to tilrekimigWritten as DupilumabReport a problem
- Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) CoformulationNot yet recruitingPhase 3SanofiNCT07919899The approved form, compared with a new hyaluronidase coformulationWritten as DupilumabReport a problem
- A Phase III Study of GS101 Injection to Dupixent®RecruitingPhase 3Jiangsu Genscend Biopharmaceutical Co., LtdNCT07386743Reference product for the biosimilar GS101Written as DUPIXENT®Report a problem
- A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic DermatitisRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07754786Reference product for the biosimilar IBI3027Written as Dupilumab InjectionReport a problem
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07399067Comparator to IBI3002Written as DupilumabReport a problem
- A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.RecruitingPhase 1Chong Kun Dang PharmaceuticalNCT07358156Reference product for the biosimilar CKD-706Report a problem
- A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male SubjectsNot yet recruitingPhase 1Gan & Lee Pharmaceuticals.NCT07334496Reference product for the biosimilar GLR1044Written as Dupilumab InjectionReport a problem
- A Phase Ⅲ Comparative Study of QL2108 to Dupixent®Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06884891Reference product for the biosimilar QL2108Written as Dupixent®Report a problem
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06868212Comparator to remibrutinib in chronic spontaneous urticariaWritten as DupilumabReport a problem
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisTerminatedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07330934Reference arm beside IBI356Written as DupilumabReport a problem
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabActive, not recruitingPhase 3AbbVieNCT06389136Comparator to upadacitinib after an inadequate responseWritten as Dupilumab 300mg DoseReport a problem
- A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisActive, not recruitingPhase 3AbbVieNCT06461897Comparator to upadacitinib in childrenWritten as DupilumabReport a problem
- A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous InjectionCompletedPhase 1Jiangsu Genscend Biopharmaceutical Co., LtdNCT07411755Reference product for the biosimilar GS101Report a problem
- An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisActive, not recruitingPhase 1Apogee Therapeutics, Inc.NCT07027527Comparator to APG777 with APG990Written as DupilumabReport a problem
- A Phase I Study of 9MW4113 Injection Versus Dupixent®Active, not recruitingPhase 1Mabwell (Shanghai) Bioscience Co., Ltd.NCT07791342Reference product for 9MW4113Written as DupilumabReport a problem
- A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)TerminatedPhase 2Janssen Research & Development, LLCNCT06881251Comparator to JNJ-95475939Written as DupilumabReport a problem
- A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese VolunteersActive, not recruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT07502534Reference product for the biosimilar IBI3027Written as DUPIXENT® (dupilumab)Report a problem
- A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis PatientsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT06193434Comparator to IBI356Report a problem
- A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®CompletedPhase 1Qilu Pharmaceutical Co., Ltd.NCT06614907Reference product for the biosimilar QL2108Written as Dupixent®Report a problem
- A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe ADCompletedPhase 2LEO PharmaNCT05470114Comparator to LEO 138559Written as Dupixent®Report a problem
Showing 20 of 26. See all 26 →
Observed · 90 — patients on it are followed, or it is given outside a trial
- ADBest TREAT RegistryRecruitingUniversitätsklinikum Hamburg-EppendorfNCT07904546Registry of atopic dermatitis treatmentsWritten as DupilumabReport a problem
- Microbiome in Atopic Dermatitis Under Systemic TherapyRecruitingCharite University, Berlin, GermanyNCT05099315One cohort of systemic treatments, observedReport a problem
- The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) RegistryRecruitingSanofiNCT07612878COPD registry (STRIDE)Written as Cohort 1: DupilumabReport a problem
- Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported OutcomesRecruitingSanofiNCT07380711Long-term in COPD, observedReport a problem
- A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in GermanyRecruitingSanofiNCT06695897Long-term in eosinophilic esophagitis, observedWritten as DupilumabReport a problem
- T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPDRecruitingShanghai Pulmonary Hospital, Shanghai, ChinaNCT07823842Real-world type 2 biologics in asthma and COPDReport a problem
- Neural Dissimilarity in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With BiologicsNot yet recruitingRigshospitalet, DenmarkNCT07819162Patients on biologics, observedReport a problem
- Compassionate Use or Expanded Access of DupilumabAvailableRegeneron PharmaceuticalsNCT04776694Compassionate use, outside a trialWritten as DupilumabReport a problem
- A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab TreatmentRecruitingSanofiNCT06192563Response in children with less extensive lesions, observedWritten as DupilumabReport a problem
- The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic DermatitisRecruitingSanofiNCT07467564On anxiety and depression in atopic dermatitis, observedWritten as DupilumabReport a problem
- Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.RecruitingNorthwestern UniversityNCT06892704Smell recovery on it, observedReport a problem
- Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With LinvoseltamabAvailableRegeneron PharmaceuticalsNCT06631677Expanded access after linvoseltamab in food allergyWritten as DupilumabReport a problem
- Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With BiologicsNot yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07602881One of three biologics in severe eosinophilic ACOS, observedReport a problem
- BIOlogics in Severe Nasal POlyposis SurvEy.: a French RegistryRecruitingNot applicableUniversity Hospital, LilleNCT06501807Registry of biologics for severe nasal polyposisReport a problem
- A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria PatientsRecruitingNovartis PharmaceuticalsNCT07408219One cohort beside remibrutinib, observedReport a problem
- Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa RicaNot yet recruitingCaja Costarricense de Seguro SocialNCT07448363Treated beside JAK inhibitors in Costa Rica, observedWritten as DupilumabReport a problem
- Registry for Systemic Eczema TreatmentsRecruitingJohns Hopkins UniversityNCT06136767Registry of systemic eczema treatmentsReport a problem
- Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world ConditionsRecruitingSanofiNCT07052396Long-term effectiveness, observedWritten as DupilumabReport a problem
- Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo NodularisRecruitingUMC UtrechtNCT07276425Early and long-term effect in prurigo nodularis, observedWritten as DupilumabReport a problem
- Dupilumab Therapy for EGIDsRecruitingChildren's Hospital of Fudan UniversityNCT07257835In eosinophilic gastrointestinal disorders, observedReport a problem
Showing 20 of 90. See all 90 →
As a tool · 1 — an imaging tracer or a test of drug response
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory DiseaseNov 13, 2026NCT05575037
Stopped1
- Dupilumab De-escalation in Pediatric Atopic DermatitisTerminatedOct 19, 2026NCT06116526
Newly registered2
- Dupilumab in Major Depressive DisorderNov 2, 2026NCT07908563
- A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisOct 29, 2026NCT07905547
Codes
What other systems call dupilumab · ClinicalTrials.gg INT006309
- MeSH (NLM) C582203dupilumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 420K487FSGDUPILUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1876376Confirmed FDA, Wikidata
- Wikidata Q5315925dupilumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C162455DupilumabOne source FDA
- DrugBank DB12159One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582203 | dupilumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 420K487FSG | DUPILUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1876376 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5315925 | dupilumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C162455 | Dupilumab | One source FDA |
| DrugBank | DB12159 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.